Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese
作者： Keiko Maekawa , Hiromi Fukushima-Uesaka , Masahiro Tohkin , Ryuichi Hasegawa , Hiroshi Kajio
DOI: 10.1097/01.FPC.0000215069.14095.C6
关键词:
摘要: Genetic variations in cytochrome P450 2C9 (CYP2C9) are known to contribute interindividual and interethnic variability response clinical drugs such as warfarin. In the present study, CYP2C9 from 263 Japanese subjects was resequenced, resulting discovery of 62 including 32
lww.com 
sci-hub.se 参考文章(40)
Craig R Lee, CYP2C9 genotype as a predictor of drug disposition in humans. Methods and Findings in Experimental and Clinical Pharmacology. ,vol. 26, pp. 463- 472 ,(2004)
David Lewis, Guide to Cytochromes P450 : structure and function CRC Press. ,(2001) , 10.1201/9781420023046
Robert Walton, Martin Kimber, Kirk Rockett, Clare Trafford, Dominic Kwiatkowski, Giorgio Sirugo, Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10 Nature Genetics. ,vol. 37, pp. 915- 916 ,(2005) , 10.1038/NG0905-915
Robert S. Kidd, Timothy B. Curry, Susan Gallagher, Timi Edeki, Joyce Blaisdell, Joyce A. Goldstein, Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. ,vol. 11, pp. 803- 808 ,(2001) , 10.1097/00008571-200112000-00008
Sabine Gerbal-Chaloin, Martine Daujat, Jean-Marc Pascussi, Lydiane Pichard-Garcia, Marie-Jose Vilarem, Patrick Maurel, Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. Journal of Biological Chemistry. ,vol. 277, pp. 209- 217 ,(2002) , 10.1074/JBC.M107228200
Kourosh R Ahmadi, Michael E Weale, Allen D Roses, Ann M Saunders, David B Goldstein, Reply to 'Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10' Nature Genetics. ,vol. 37, pp. 916- 916 ,(2005) , 10.1038/NG0905-916
M Shintani, Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clinical Pharmacology & Therapeutics. ,vol. 70, pp. 175- 182 ,(2001) , 10.1067/MCP.2001.117367
Kenji Takanashi, Hitoshi Tainaka, Kaoru Kobayashi, Toshio Yasumori, Masakiyo Hosakawa, Kan Chiba, CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. ,vol. 10, pp. 95- 104 ,(2000) , 10.1097/00008571-200003000-00001
Armelle Melet, Nadine Assrir, Pascale Jean, Maria Pilar Lopez-Garcia, Cristina Marques-Soares, Maryse Jaouen, Patrick M Dansette, Marie-Agnès Sari, Daniel Mansuy, Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid Archives of Biochemistry and Biophysics. ,vol. 409, pp. 80- 91 ,(2003) , 10.1016/S0003-9861(02)00548-9
Craig R. Lee, Joyce A. Goldstein, John A. Pieper, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. ,vol. 12, pp. 251- 263 ,(2002) , 10.1097/00008571-200204000-00010